Anchored in IP licensed from Virgina Tech, Techulon™, Inc. is addressing idevelopment, manufacture and commercialization of biopolymers and is focused to next generation of disease treatment through development of safe and effective treatments for drug resistant infections. The firm's lead candidate is targeted at MRSA. The company uses a proven method to defeat bacteria at the genomic level. Unlike current antibiotics on the market, the drugs that are derived from Techulon’s approach are potent and not susceptible to resistance.Techulon's enabling technology is a robust platform that allows for delivery of nucleic acids for a variety of therapeutic applications. Recent work on an antimicrobial platform using a novel informatics approach, the company has identified new gene targets and is developing antimicrobial therapeutics for broad applications. The firm spectializes in Synthetic polymers for life science applications and drug delivery, transfection reagents, cell therapy delivery, biodegradable transfection reagents
